To find potential immunotherapeutic targets for gliomas, researchers might look at the functional, molecular, and geographical heterogeneity of tumor-associated immune cells.[57] MXD3 encodes a member of the Myc superfamily of basic helix-loop-helix leucine zipper transcriptional regulators. Here, MYC is linked to central nervous system cancer.